Renal Denervation: A Promising Treatment for Hypertension
Introduction
Renal denervation (RDN) is a neuromodulation therapy that has shown promise in treating high blood pressure (hypertension). The procedure involves using an intraarterial catheter to deliver radiofrequency energy to the renal arteries, which supply blood to the kidneys. This energy disrupts the sympathetic nerves that contribute to hypertension.
Recent Developments
In 2023, the US Food and Drug Administration (FDA) approved RDN for use in adults with uncontrolled or resistant hypertension who are taking three or more antihypertensive medications. This approval was based on clinical trials that showed RDN significantly lowered blood pressure in these patients.
Benefits of RDN
RDN has several potential benefits over traditional antihypertensive medications:
*Conclusion
Renal denervation is a promising new treatment for hypertension. The FDA approval of RDN in 2023 represents a significant step forward in the management of this common condition. Further research is needed to confirm the long-term effectiveness of RDN and to explore its potential use in a broader population of patients.
Komentar